This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates
Newswire.ca - Tue Nov 7, 2023
Preliminary data for FPI-2265 (225Ac-PSMA I&T) in approximately 20 to 30 patients on track for Q1 2024
Data from Cohort 2 of the FPI-1434 Phase 1 study anticipated around year-end 2023